Table 2.
Survival and limitation of life sustaining treatments in both cohorts
| COVID patients | Non-COVID patients | p-value | |
|---|---|---|---|
| (n = 693) | (n = 1393) | ||
| Overall survival (OS) | |||
| At 1 days (range) | 97% (96–98) | 97% (96–98) | < 0.001 |
| At 3 days (range) | 87% (85–90) | 89% (87–90) | |
| At 7 days (range) | 72% (69–75) | 77% (74–79) | |
| At 30 days (range) | 38% (35–42) | 57% (55–60) | |
| Withholding LST | |||
| Yes | 267 (39.1%) | 456 (33.1%) | 0.009 |
| Withdrawing LST | |||
| Yes | 136 (19.9%) | 212 (15.4%) | 0.012 |
| Time admission—withholding | |||
| Med (range) (IQR) | 2 (− 6 to 50) (1–6) | 1 (− 2 to 80) (1–4) | 0.094 |
| Time withholding—death | |||
| Med (range) (IQR) | 4 (0–71) (1.5–7) | 3 (0–184) (1–7) | 0.27 |
| Time admission—withdrawing | |||
| Med (range) (IQR) | 7 (1–46) (4–13) | 4 (1–54) (2–7) | < 0.0001 |
| Time withdrawing—death | |||
| Med (range) (IQR) | 0 (0–18) (0–1) | 0 (0–165) (0–1) | 0.49 |
ADL Activity of daily living, CFS clinical frailty scale, NIV non invasive mechanical ventilation, LOS length of stay, LST life sustaining therapy